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Abstract
The 2016 revision of the WHO classification for lymphoma classification has included a new category of lymphoma, separate from diffuse large B-cell lymphoma termed High grade B-cell lymphoma with translocations involving myc and bcl-2 or bcl-6. These lymphomas, which occur in less than 10% of cases of diffuse large B-cell lymphoma, have been referred to as "double hit" lymphomas (or triple hit lymphomas if all three rearrangements are present). It is important to differentiate these lymphomas from the larger group of "double expressor" lymphomas which have increased expression of MYC and BCL-2 and/or BCL-6 by immunohistochemistry, using variable cut-off percentages to define positivity. Double hit lymphomas have a poor prognosis when treated with standard chemoimmunotherapy, and have increased risk of central nervous system involvement and progression. Double hit lymphomas may arise as a consequence of transformation of underlying indolent lymphoma. There are no published prospective trials in double hit lymphoma, however retrospective studies strongly suggest that "aggressive" induction regimens may confer superior outcome. In this manuscript, I review my approach to the evaluation and treatment of double hit lymphoma, with an eye toward future clinical trials incorporating rational targeted agents into the therapeutic armamentarium.
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Case Presentation 1
A 53 year old man presents with a two month history of left hip pain. He did not respond to initial conservative management, including rest and physical therapy. MRI of the left hip was eventually performed, which showed a destructive, enhancing lesion involving the left iliac wing, acetabulum and pubic ramus, measuring 8x7x7 cm. Computed tomographic scan of chest, based upon the international prognostic index, and the age adjusted international prognostic index. 1 Subsequent immunohistochemical stains revealed the lymphoma to be positive for BCL-6, BCL-2 and MYC, and negative for CD10, CD30, MUM1 and EBER; Ki-67 fraction was 50%. This suggests the tumor is of germinal center origin (using the Hans algorithm 2 ) and a
international prognostic index. The patient was started on dose-adjusted EPOCH therapy, and tolerated two cycles well. A lumbar puncture for planned prophylaxis with intrathecal methotrexate was performed as part of cycle 3, and results of CSF analysis revealed the presence of large lymphoid forms with high nuclear:cytoplasmic ratio, fine chromatin and vacuoles, which were confirmed as clonal on flow cytometry, consistent with CNS involvement by high grade B-cell lymphoma with myc and bcl-2 rearrangements.
Introduction: Myc-associated lymphoma
cMyc is an essential "global" transcription factor and has roles in proliferation and cellular growth. This gene, located on chromosome 8q24, is normally carefully regulated which results in low c-MYC protein levels, and has the ability to induce apoptosis under normal physiological conditions. The c-myc gene has long been recognized as a bona fide oncogene, and may transform cells via unregulated overexpression of intact c-MYC protein through insertional mutagenesis, gene amplification, and chromosomal translocation. 3 The c-myc gene translocation with an immunoglobulin gene is the genetic hallmark of Burkitt lymphoma, and required to make this diagnosis. 4 5 Diffuse large B-cell lymphoma is the most common lymphoma diagnosed in the Western world, and is curable in approximately two thirds of cases with standard chemoimmunotherapy approaches. This disease exhibits significant clinical heterogeneity, and prognostic scoring systems utilizes clinical factors (for example age, stage, performance status, serum lactate dehydrogenase level, and number of extranodal sites involved) to successfully stratify outcomes in the modern era. 6, 7 These clinical factors largely represent surrogates for genetic and molecular factors within the tumor. Cell-of-origin studies have revealed at least three major subtypes of diffuse large B-cell lymphoma: activated B-cell (ABC), germinal center (GCB) and primary mediastinal; these subtypes not only constitute unique molecular entities, but also have differential clinical outcomes using modern therapy. 8 Alternative strategies of organizing gene expression data emphasize this heterogeneity of DLBCL, with subsets characterized by signatures of host response, oxidative phosphorylation, and B-cell receptor pathway elements. c-MYC protein expression is increased in up to one third of cases of diffuse large B-cell lymphoma, suggesting that changes in myc may be an important secondary transforming event.
Using an immunohistochemical approach to assess MYC protein expression in formalin-fixed In this manuscript I will focus on the approach to double hit lymphomas involving myc and bcl-2
translocations. There is limited data to guide the therapeutic approach to myc-rearranged lymphomas involving bcl-6 translocations, and at present I would approach double hit lymphomas involving bcl-6 and triple hit lymphomas in the same manner as double hit lymphomas involving bcl-2 translocations. An important point to emphasize is that this manuscript focuses on double hit lymphomas (requiring translocations of myc and either bcl-2 or bcl-6 detected usually by FISH fluorescent in situ hybridization), not the larger subset of lymphomas that have increased expression of MYC measured by immunohistochemistry, as noted in figure 2.
Which lymphomas should be evaluated for double hit status?
At our institution, every newly diagnosed aggressive large B-cell lymphoma is referred for FISH testing with a myc break-apart probe, as well as for bcl-2 translocation, t(14;18). The WHO emphasizes that there no consensus on which large B-cell lymphomas should undergo this testing. Testing all cases clearly may increase diagnostic costs, and substantially increase the testing burden in FISH laboratories. Strategies suggested to limit FISH testing include restricting the testing to those lymphomas that are GCB subtype by immunohistochemistry, restricting the testing to highly proliferative lymphomas measured by Ki-67, and/or restricting the testing to those lymphomas that express MYC protein by immunohistochemistry.
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In a recent analysis from British Columbia, the incidence of myc and bcl-2 genetic alterations and their clinical significance were largely dependent on cell-of-origin subtypes. In the setting of myc translocation, bcl-2 translocation association with poor outcome was limited to GCB lymphoma. 26 Importantly, cell-of-origin was determined using the Lymph2Cx assay 27 in this analysis rather than an immunohistochemistry algorithm, which is most commonly used in the clinic. 8 Given known discrepancies between gene expression profiling with Lymph2Cx and immunohistochemistry algorithms in classifying DLBCL, I think it is premature to conclude that
only GCB lymphomas should be tested for double hit status with FISH, unless Lymph2Cx or a similar platform is used to determine cell-of-origin.
There are similar limitations to using Ki-67 proliferation index or MYC expression on immunohistochemistry to determine which cases should be referred for FISH evaluation of translocations. A recently published analysis of 209 cases of aggressive lymphoma included 7.4% of the cases which were double hit. MYC-positive DLBCL showed higher median Ki-67 (>90%) and CD10 positivity (as a surrogate for GCB) as compared with MYC-negative cases.
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The authors recommended a cut-off value of >/=30% for MYC by IHC; however, this has not been validated, and there are reports of cases of myc rearranged lymphoma that are below that threshold for detection. For example, in a study from the University of Pennsylvania, double hit status could not be inferred by any baseline disease-or patient-related characteristics. 29 In toto, I believe these findings support the practice of routine performance of FISH in large cell lymphoma to detect double hit status. If resources preclude this broad approach, the majority of double hit cases are GCB subtype (see figure 2 ) and express MYC on IHC, so limiting testing to this group is an acceptable, but inferior alternative.
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In addition to de novo disease, double hit lymphoma occurs in the setting of transformation of underlying indolent lymphoma, particularly follicular lymphoma, when this t(14;18) lymphoma acquires a myc translocation. 31 In one retrospective series, 21% of transformed follicular lymphomas were double hit lymphomas 32 , emphasizing the importance of incorporating FISH testing for myc rearrangement into the diagnostic algorithm for this group of patients.
How do I evaluate patients with double hit lymphoma?
Patients with double hit lymphoma should undergo routine staging procedures including baseline functional and anatomic imaging with PET/CT scans, bone marrow aspirate and 
a subset analysis of the SWOG 9704 study, 41 , which randomized patients to either 8 cycles of R-CHOP or 6 cycles of R-CHOP followed by ASCT, lymphomas with MYC expression were morphologically and phenotypically heterogeneous and were associated with poor progressionfree and overall survival in multivariate analysis. 42 All patients with double hit lymphoma died whether or not they received ASCT. 43 Finally, in a series of 163 patients treated at 17 United States academic medical centers, patients with double hit lymphoma who achieve complete remission with induction therapy do not appear to benefit from consolidation with high dose therapy and ASCT. 44 However, for a subset of patients who received induction with RCHOP (rather than a more aggressive regimen) ASCT appeared to prolong progression-free survival.
In another analysis of pooled data from a multicenter retrospective analysis, patients with double hit lymphoma were treated with R-CHOP or "intensive" induction therapy, which included 
ASH demonstrating no differences between the two regimens. 48 Although subset analyses from that trial are ongoing, it is unlikely that there will be a sufficient number of patients with double hit disease on that trial to make definitive conclusions about whether R-EPOCH is truly better than RCHOP. Further support of the R-EPOCH regimen is provided by results from a German randomized trial in younger patients with high-risk aggressive B-cell lymphoma demonstrating high event-free survival with the R-CHOEP-14 regimen, which, similar to R-EPOCH, intensifies treatment interval and incorporates etoposide into the regimen.
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Despite the limitations to these data, I currently approach most patients with double hit lymphoma using the dose-adjusted R-EPOCH regimen. The National Clinical Trials network is planning to conduct a randomized trial for patients with double expressor lymphoma, including double hit lymphoma. In this trial, dose-adjusted R-EPOCH will be the chemoimmunotherapy backbone, demonstrating a consensus across Alliance, ECOG and SWOG lymphoma committees that dose-adjusted R-EPOCH is an appropriate induction option for most patients with double hit lymphoma.
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How do I treat patients with double hit lymphoma occurring in setting of transformed follicular lymphoma?
As previously noted, it is not uncommon for patients with follicular lymphoma who experience histologic transformation to acquire a myc translocation, resulting in a double hit lymphoma.
There are no trials to guide management of these patients, who again are often elderly, and not infrequently extensively pretreated with various chemotherapy regimens for follicular lymphoma.
In patients who have not had prior anthracycline, I generally consider dose-adjusted R-EPOCH as for de novo double hit lymphoma. For the majority of other patients who have had prior anthracycline, I consider a salvage lymphoma regimen followed by ASCT. 31 In several studies of transformed lymphoma, ASCT consolidation appears to provide benefit even in the rituximab era. [57] [58] [59] The benefit of ASCT on patients with double hit transformation has not been established in these studies, but no doubt a subset of patients included in these retrospective analyses of transformed lymphomas had double hit lymphoma at time of transformation.
Relapsed double hit lymphoma, and novel agents
The standard curative approach to the treatment of relapsed aggressive lymphoma in patients who are fit is to administer non cross resistant salvage chemotherapy followed by consolidation with high dose therapy and ASCT. 60 Recent studies have suggested, not surprisingly, that outcomes of salvage chemotherapy and ASCT are poor for patients with myc-rearranged disease. For example, in the BIO CORAL study, patients with double hit disease defined by FISH had extremely poor outcomes with either R-DHAP or R-ICE salvage therapy and ASCT.
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In a recently published larger series of 117 patients examining the role of ASCT in double expressor and double hit lymphomas, the outcome of patients with double expressor and double hit lymphoma was dismal (4-year PFS, 0% 
Conclusion: Decisions on Cases
For the patient presented in the first case, given the triple hit status and retrospective studies suggesting a benefit to "aggressive" induction approaches, I would advise that the patient be switched to dose adjusted R-EPOCH for subsequent cycles. He should receive a total of 6 cycles of induction therapy, with appropriate dose-escalations as mandated in the original publications of R-EPOCH. 72 I would sample the CSF and plan prophylaxis with intrathecal methotrexate for four cycles if CSF were negative. I would restage him with a PET/CT scan at completion of treatment, and, presuming he achieves a complete remission, follow him without consolidation or transplantation. Given the high risk nature of the bone destruction, I would immediately consult with an orthopedic surgical oncologist to ensure there is stability and no rod placement is indicated. 73 Finally, I would consider radiation therapy 74 as consolidation given the destructive bulky mass and morbidity associated with local recurrence.
For the patient in the second case, he was started on appropriate induction therapy for double hit lymphoma with dose adjusted R-EPOCH. At baseline, CNS risk score was high given renal involvement and high risk IPI. 51 There is now evidence of leptomeningeal involvement given documented malignant cells in the CSF. As previously noted, this is a common site leading to treatment failure in double hit lymphoma, and unfortunately his expected outcome is poor. 
adequately penetrate the CNS. There is inadequate data to guide management for this uncommon, high risk scenario. A recently published phase two study demonstrated efficacy of high dose methotrexate and cytarabine, followed by intensification and high dose therapy and ASCT for secondary CNS lymphoma. 75 Thirty eight patients were enrolled; only 20 were able to proceed to ASCT, but outcome in this subgroup was favorable. Double hit status was not reported. These results are similar to another phase 2 trial incorporating thiotepa into ASCT after aggressive salvage therapy. 76 Based upon these experiences, I would alternate the high dose methotrexate/cytarabine combination with the remaining cycles of dose-adjusted R-EPOCH, and then consider consolidation with high dose therapy and ASCT using thiotepa based conditioning.
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For "Double Hit": high grade lymphoma with rearrangements of myc and bcl-2 or myc and bcl-6. These must be diagnosed with FISH, or more advanced genomic techniques.
"Triple Hit": high grade lymphoma with rearrangements of myc and bcl-2 and bcl-6. These must be diagnosed with FISH, or more advanced genomic techniques.
"Double expressor": protein expression of myc and bcl-2 and/or bcl-6. These are measured using an immunohistochemistry cut-off for percentage of positive cells.
For and/or bcl-6 rearrangements (double hit) usually, but not always falls in the double expressor group, but in GCB subtype. Additionally, morphology of this group may include Burkitt-like.
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